Current practices on genetic testing in ovarian cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Epithelial ovarian cancer (EOC) has a high rate of hereditary cases, with 20-25% of patients carrying pathogenic variants (PVs).
• Many identified PVs are in genes crucial for DNA repair pathways, particularly homologous recombination (HR) and mismatch repair (MMR).
• BRCA1 and BRCA2 are key genes associated with hereditary ovarian cancer, with additional HR pathway genes also implicated.

Purpose of the Study:

• To review the clinical implications of genetic testing in epithelial ovarian cancer.
• To guide the referral of ovarian cancer patients for genetic counseling and testing.
• To discuss the timing and prognostic/predictive value of genetic testing, especially concerning BRCA status.

Main Methods:

• Literature review of studies on hereditary ovarian cancer genetics.
• Analysis of the role of DNA repair pathways (HR and MMR) in EOC.
• Discussion of clinical applications of genetic testing results.

Main Results:

• Pathogenic variants in DNA repair genes are common in EOC patients.
• Identification of HR deficiency impacts chemotherapy and targeted therapy choices (e.g., PARP inhibitors).
• Genetic testing provides prognostic and predictive value for ovarian cancer management.

Conclusions:

• Genetic testing is crucial for identifying hereditary ovarian cancer and informing treatment strategies.
• Timely genetic counseling and testing can optimize patient care and outcomes.
• Understanding a patient's BRCA status and HR deficiency is vital for personalized ovarian cancer therapy.